Pharmacyclics, Inc. - All News Releases
Pharmacyclics, Inc. - All News Releases
IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study
Posted: May 31, 2014, 12:05 pm
IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases
Posted: May 31, 2014, 12:05 pm
IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL
Posted: May 31, 2014, 12:05 pm
Pharmacyclics appoints Gregory R. Wade to lead Business Development
Posted: May 20, 2014, 12:00 pm
Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies
Posted: May 14, 2014, 10:22 pm
Pharmacyclics Reports First Quarter 2014 Results
Posted: May 2, 2014, 12:00 pm
Pharmacyclics Announces Date of Conference call to discuss Financial Results for First Quarter of 2014
Posted: April 25, 2014, 2:45 pm
Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO
Posted: April 21, 2014, 3:45 pm
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data
Posted: April 8, 2014, 12:00 pm
Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results
Posted: February 20, 2014, 9:01 pm